Try our beta test site
152 studies found for:    "Biliary tract cancer"
Show Display Options
Rank Status Study
1 Completed Second Line Therapy in Advanced Biliary Tract Cancer
Condition: Biliary Tract Cancer
Interventions: Drug: capecitabine and mitomycin;   Drug: Capecitabine
2 Active, not recruiting Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer Who Failed Gemcitabine-based Combination Chemotherapy
Condition: Biliary Tract Cancer
Intervention: Drug: Lenvatinib
3 Withdrawn Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers
Condition: Biliary Tract Cancer
Intervention: Drug: Irinotecan & Capecitabine
4 Completed Vessel Resection and Reconstruction of Biliary Tract Cancers
Condition: Biliary Tract Cancer
Intervention:
5 Completed Case Series Study of Biliary Tract Cancer Patients in Japan
Condition: Biliary Tract Cancer
Intervention:
6 Completed A Population-Based Case-Control Study of Biliary Tract Cancers in Shanghai, China
Condition: Biliary Tract Cancer
Intervention:
7 Active, not recruiting GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer
Condition: Biliary Tract Cancer
Interventions: Drug: Gemcitabine/Cisplatin;   Drug: Gemcitabine/Cisplatin /S-1
8 Recruiting MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer
Condition: Biliary Tract Cancer
Intervention: Drug: MEK162+capecitabine
9 Recruiting A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer
Condition: Unresectable Biliary Tract Cancer
Intervention: Drug: nab-paclitaxel in combination with gemcitabine + cisplatin
10 Completed Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer
Condition: Biliary Tract Cancer
Interventions: Drug: Gemcitabine;   Drug: S-1
11 Completed Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer
Condition: Biliary Tract Cancer
Intervention: Drug: S-1, Gemcitabine, Cisplatin
12 Active, not recruiting Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer
Condition: Biliary Tract Cancer
Interventions: Drug: Gemcitabine;   Drug: S-1
13 Unknown  Docetaxel and Oxaliplatin Combination With Locally Advanced or Metastatic Biliary Tract Cancer
Condition: Biliary Tract Cancer
Intervention: Drug: Docetaxel, Oxaliplatin
14 Completed
Has Results
Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer
Condition: Biliary Tract Cancer
Interventions: Drug: gemcitabine;   Drug: cisplatin
15 Unknown  Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma)
Condition: Biliary Tract Cancer
Intervention: Drug: S-1 oxaliplatin
16 Active, not recruiting Oral Rehydration Therapy for Short Hydration in Chemotherapy With CDDP Plus GEM for Biliary Tract Cancer
Condition: Biliary Tract Cancer
Interventions: Drug: Gemcitabine , Cisplatin, Oral Rehydration Solution (ORS);   Drug: Gemcitabine , Cisplatin
17 Unknown  Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer
Condition: Biliary Tract Cancer
Interventions: Drug: Fluorouracil;   Drug: Leucovorin;   Drug: Oxaliplatin;   Drug: Irinotecan
18 Active, not recruiting A Phase I Study of Adjuvant Chemotherapy With GS in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy
Condition: Biliary Tract Cancer
Intervention: Drug: Gemcitabine, S-1
19 Completed A Phase I Study of Adjuvant Chemotherapy With GC in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy
Condition: Biliary Tract Cancer
Intervention: Drug: gemcitabine , cisplatin
20 Recruiting A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis
Condition: Biliary Tract Cancer
Intervention: Drug: Gemcitabine, Cisplatin, S-1

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.